{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007079","form_type":"8-K","ticker":"CCEL","cik":"0000862692","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.302257+00:00","generated_at":"2026-06-18T08:03:36.004068+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study","bullets":["Second Amendment removes final license fee payment to Duke; license fee now paid in full.","New milestone payment triggered upon FDA approval of first cord tissue MSC product for autism spectrum disorder.","New milestone requires Cryo-Cell to open manufacturing facility for licensed product before Phase III trial initiation.","Cryo-Cell entered Research Agreement to fund Duke IMPACT Study; 14 monthly payments starting April 2023.","IMPACT Study targeted accrual reached: 137 patients; draft publication due no later than September 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007079","json":"https://secwatch.observer/filing/0000950170-23-007079.json","markdown":"https://secwatch.observer/filing/0000950170-23-007079.md","text":"https://secwatch.observer/filing/0000950170-23-007079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/0000950170-23-007079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/ccel-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:03:36.004068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b401d94c2ad1aff10e5eeb053a209421b8ef7109","claim":"CRYO CELL INTERNATIONAL INC entered into Clinical Study and Research Agreement with Duke valued at 14 equal monthly payments commencing in April 2023 and a final payment (effective 2023-03-03).","evidence_excerpt":"As part of the Second Amendment, on March 3, 2023, the Company entered into the Clinical Study and Research Agreement (the “Research Agreement”) with Duke to provide funding to complete the Duke IMPACT Study","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/0000950170-23-007079-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Duke"},{"label":"Value","value":"14 equal monthly payments commencing in April 2023 and a final payment"},{"label":"Effective","value":"2023-03-03"}],"fact_type":"material_agreement"},{"claim_id":"e290fe600c4aaf3979e02e89ebdf12811201bafb","claim":"CRYO CELL INTERNATIONAL INC amended Second Amendment to the License Agreement with Duke (effective 2023-02-17).","evidence_excerpt":"On February 17, 2023, Cryo-Cell International, Inc. (\"Company\") entered into a Second Amendment to the License Agreement (the “Second Amendment”) with Duke","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/0000950170-23-007079-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Duke"},{"label":"Effective","value":"2023-02-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}